Literature DB >> 16496290

Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease.

Steven J Ambrusko1, Sriya Gunawardena, Allison Sakara, Beth Windsor, Lizabeth Lanford, Peter Michelson, Lakshmanan Krishnamurti.   

Abstract

BACKGROUND: Pulmonary hypertension (PHTN) is a potentially life-threatening complication, detected by echocardiographic evidence of elevated tricuspid regurgitant velocity (TRV). This condition has been described in adults with sickle cell disease (SCD) and other hemolytic disorders; however, there is little information on the occurrence of this condition in pediatric patients.
METHODS: Records for pediatric SCD patients were retrospectively reviewed to determine clinical characteristics and co-morbidities of patients with elevated TRV on echocardiograms obtained under steady state conditions as an outpatient. Correlation of TRV > or =2.5 m/sec with age, sex, type of SCD, number of outpatient echocardiograms per patient, episodes of vasoocclusive crisis (VOC) and acute chest syndrome (ACS), mean hemoglobin and reticulocyte count, asthma, obstructive sleep apnea, cerebrovascular disease (CVD), and hydroxyurea therapy was determined.
RESULTS: Of 224 SCD patients, 44 had outpatient echocardiographic measurement of TRV. Patients (11 of 44) (26.2%) with TRV > or =2.5 m/sec were compared to 31 patients without elevated TRV. Significant differences were noted for percent with HbSS disease (P = 0.041), CVD (P = 0.021), hemoglobin (P = 0.003), % reticulocytes (P = 0.037), and number of echocardiograms performed (P < 0.001). No significant differences were observed for gender, age, asthma, or frequency of VOC and ACS.
CONCLUSIONS: Elevated TRV, a surrogate marker for PHTN, occurs in children with SCD and is associated with low hemoglobin, elevated reticulocyte count, and cerebral vasculopathy. Appropriate screening by echocardiography can lead to detection and treatment that may reduce TRV and potentially reverse the disease process, prevent the increased morbidity and mortality associated with PHTN.

Entities:  

Mesh:

Year:  2006        PMID: 16496290     DOI: 10.1002/pbc.20791

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  29 in total

1.  Vascular risk assessment in patients with sickle cell disease.

Authors:  Claudia R Morris
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

2.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

3.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

4.  Changes in Bi-ventricular Function After Hematopoietic Stem Cell Transplant as Assessed by Speckle Tracking Echocardiography.

Authors:  Stuart Covi; Yaddanapudi Ravindranath; Ahmad Farooqi; Sureyya Savasan; Roland Chu; Sanjeev Aggarwal
Journal:  Pediatr Cardiol       Date:  2017-11-01       Impact factor: 1.655

5.  Alternative donor hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Andrew L Gilman; Michael J Eckrich; Stacy Epstein; Carrie Barnhart; Mark Cannon; Tracy Fukes; Michelle Hyland; Krishna Shah; Darci Grochowski; Elizabeth Champion; Anastasia Ivanova
Journal:  Blood Adv       Date:  2017-06-28

6.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

Review 7.  Pulmonary hypertension in sickle cell disease: relevance to children.

Authors:  Gregory J Kato; Onyinye C Onyekwere; Mark T Gladwin
Journal:  Pediatr Hematol Oncol       Date:  2007 Apr-May       Impact factor: 1.969

8.  Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease.

Authors:  Niti Dham; Gregory Ensing; Caterina Minniti; Andrew Campbell; Manuel Arteta; Sohail Rana; Deepika Darbari; Mehdi Nouraie; Onyinye Onyekwere; Malgorzata Lasota; Gregory J Kato; Mark T Gladwin; Oswaldo Castro; Victor Gordeuk; Craig Sable
Journal:  Am J Cardiol       Date:  2009-06-24       Impact factor: 2.778

9.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 10.  Clinical practice. The impact of lung disease on the heart and cardiac disease on the lungs.

Authors:  Fiona Healy; Brian D Hanna; Raezelle Zinman
Journal:  Eur J Pediatr       Date:  2009-07-29       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.